KR20150010973A - 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 - Google Patents

피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Download PDF

Info

Publication number
KR20150010973A
KR20150010973A KR20147033843A KR20147033843A KR20150010973A KR 20150010973 A KR20150010973 A KR 20150010973A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20150010973 A KR20150010973 A KR 20150010973A
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
methyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147033843A
Other languages
English (en)
Korean (ko)
Inventor
마르크 나자레
데틀레프 코지안
안드레아스 에베르스
베른가르트 체흐티즈키
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20150010973A publication Critical patent/KR20150010973A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20147033843A 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Ceased KR20150010973A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305552.7 2012-05-18
EP12305552 2012-05-18
PCT/EP2013/060171 WO2013171317A1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
KR20150010973A true KR20150010973A (ko) 2015-01-29

Family

ID=48446368

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147033843A Ceased KR20150010973A (ko) 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도

Country Status (22)

Country Link
US (1) US9346762B2 (https=)
EP (1) EP2882715B1 (https=)
JP (1) JP6257596B2 (https=)
KR (1) KR20150010973A (https=)
CN (1) CN104302625B (https=)
AU (1) AU2013261718B2 (https=)
BR (1) BR112014028406A2 (https=)
CA (1) CA2871542A1 (https=)
CY (1) CY1118618T1 (https=)
DK (1) DK2882715T3 (https=)
ES (1) ES2612205T3 (https=)
HR (1) HRP20170098T1 (https=)
HU (1) HUE032890T2 (https=)
IL (1) IL235221A (https=)
LT (1) LT2882715T (https=)
MX (1) MX347615B (https=)
PL (1) PL2882715T3 (https=)
PT (1) PT2882715T (https=)
RU (1) RU2645344C2 (https=)
SG (1) SG11201407210SA (https=)
SI (1) SI2882715T1 (https=)
WO (1) WO2013171317A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850062B1 (en) 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
BR112017026535B1 (pt) 2015-06-12 2023-12-19 Vettore, LLC Composto e composição farmacêutica
WO2018111904A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
PL4038052T3 (pl) 2019-10-02 2024-08-26 Domain Therapeutics Antagoniści receptora ep4 prostaglandyny e2 (pge2)
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
CN119930520B (zh) * 2023-11-03 2026-03-06 中国药科大学 N-芳基吡唑类化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
EA019711B1 (ru) * 2008-03-07 2014-05-30 Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40
KR20110128942A (ko) * 2009-03-19 2011-11-30 사노피 Ｈｓｐ９０ 억제 인다졸 유도체, 그를 함유하는 조성물 및 그의 용도
GEP20135879B (en) 2009-08-03 2013-07-10 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates
ES2530345T3 (es) * 2010-09-02 2015-03-02 Merck Patent Gmbh Derivados de pirazolopiridinona como antagonistas del receptor del LPA
EP2850062B1 (en) 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation

Also Published As

Publication number Publication date
SI2882715T1 (sl) 2017-03-31
EP2882715A1 (en) 2015-06-17
SG11201407210SA (en) 2014-12-30
US9346762B2 (en) 2016-05-24
JP6257596B2 (ja) 2018-01-10
DK2882715T3 (en) 2017-02-13
CA2871542A1 (en) 2013-11-21
AU2013261718A1 (en) 2014-12-18
RU2014151360A (ru) 2016-07-10
CN104302625B (zh) 2017-04-19
US20150141477A1 (en) 2015-05-21
CN104302625A (zh) 2015-01-21
PL2882715T3 (pl) 2017-04-28
CY1118618T1 (el) 2017-07-12
MX2014014011A (es) 2015-02-12
HUE032890T2 (hu) 2017-11-28
IL235221A (en) 2016-06-30
BR112014028406A2 (pt) 2017-06-27
WO2013171317A1 (en) 2013-11-21
JP2015517514A (ja) 2015-06-22
ES2612205T3 (es) 2017-05-12
RU2645344C2 (ru) 2018-02-21
LT2882715T (lt) 2017-02-10
PT2882715T (pt) 2016-12-30
EP2882715B1 (en) 2016-11-09
HRP20170098T1 (hr) 2017-03-24
MX347615B (es) 2017-05-04
AU2013261718B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CN116082303B (zh) 新型氧代吡啶类化合物及其中间体和应用
JP6884801B2 (ja) 血漿カリクレインインヒビターとしてのピラゾール誘導体
KR20150010973A (ko) 피라졸 유도체 및 lpar5 길항제로서의 그의 용도
CN102239164A (zh) 2h-色烯化合物及其衍生物
KR20170090451A (ko) 혈장 칼리크레인의 저해제로서의 n-((het)아릴메틸)-헤테로아릴-카르복사미드 화합물
HK1214247A1 (zh) 作為細胞凋亡信號調節激酶抑制劑的經取代的吡啶-2-甲酰胺化合物
EA015942B1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
CN110101700A (zh) 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
KR102947730B1 (ko) 염증성 기도 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 1-(6-(메톡시)피리다진-3-일)사이클로프로판-1-카르복사미드 유도체
CN105209440B (zh) 作为凝血酶抑制剂的卤代吡唑
JP2022527618A (ja) Ｔｒｐｃ６阻害剤
EP2850062B1 (en) Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
KR20150016304A (ko) 벤조[1,3]디옥신 유도체 및 lpar5 길항제로서의 그의 용도
TW202235078A (zh) 自分泌運動因子（ａｕｔｏｔａｘｉｎ）之新穎的抑制劑
JP2011503022A (ja) レニン阻害剤としての４，４−二置換ピペリジン
JP7458984B2 (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
WO2019144811A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
HK40096093A (en) Novel inhibitors of autotaxin
HK40096093B (en) Novel inhibitors of autotaxin
HK40035558A (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
EA042646B1 (ru) Пиридазины
JP2006516127A (ja) ホスホジエステラーゼ４阻害剤としてのフタラジン誘導体
KR20130131775A (ko) 인자 ＸＩａ 억제 활성을 갖는 다이펩타이드 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190812

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190812

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I